To: Jan Larsson
Sent by email: **jan.olov.larsson@telia.com**

MHRA
151 Buckingham Palace Road
London SW1W 9SZ
United Kingdom

mhra.gov.uk

12 June 2014

RE: Email received 4 July 2014

Dear Mr Larsson

Thank you for your recent correspondence. We have responded to you fully on multiple occasions on all the points you have raised, with the exception of the questions relating to ongoing procedures in Europe that involve a the long-acting formulation of Ritalin – "Ritalin LA".

Please note that Ritalin LA is not authorised for use in the UK. Therefore, the MHRA has not been involved in any work sharing assessment concerning Ritalin LA in any other European member state.

Consequently, we will not be making any further comments to you regarding the ongoing procedures relating to Ritalin LA.

Yours sincerely



Dr Ian Hudson
Chief Executive, MHRA
Telephone: +44 (0)20 3080 6100
Email: Ian.Hudson@mhra.gsi.gov.uk

The information supplied in response to your request is the copyright of MHRA and/or a third party or parties, and has been supplied for your personal use only. You may not sell, resell or otherwise use any information provided without prior agreement from the copyright holder. For full details on our copyright policy please visit: http://www.mhra.gov.uk/home/Idcplg?IdcService=SS_GET_PAGE&nodeId=412
Or e-mail the MHRA Information Centre at info@mhra.gsi.gov.uk